A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins.
Walker
R E
RE
National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA.
D000998:Antiviral Agents / Q000627:therapeutic use; D002985:Clinical Protocols; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D004200:Diseases in Twins / Q000628:therapy*; D004992:Ethics, Medical; D005813:Genes, Synthetic; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods; D010865:Pilot Projects; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000235:genetics*; D012449:Safety; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*; D014184:Transplantation, Homologous; D014430:Twins, Monozygotic
D000998:Antiviral Agents; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins